An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Recent studies showed that the PD-1/PD-L1 checkpoint blockade is a dramatic therapy for melanoma by enhancing antitumor immune activity. Currently, major strategies for the PD-1/PD-L1 blockade have mainly focused on the use of antibodies and compounds. Seeking an alternative approach, others employ endogenous proteins as blocking agents. The extracellular domain of PD-1 (ePD1) includes the binding site with PD-L1. Accordingly, we constructed a PD-1-based recombinantly tailored fusion protein (dFv-ePD1) that consists of bivalent variable fragments (dFv) of an MMP-2/9-targeted antibody and ePD1. The melanoma-binding intensity and antitumor activity were also investigated. We found the intense and selective binding capability of the protein dFv-ePD1 to human melanoma specimens was confirmed by a tissue microarray. In addition, dFv-ePD1 significantly suppressed the migration and invasion of mouse melanoma B16-F1 cells, and displayed cytotoxicity to cancer cells in vitro. Notably, dFv-ePD1 significantly inhibited the growth of mouse melanoma B16-F1 tumor cells in mice and in vivo fluorescence imaging showed that dFv-ePD was gradually accumulated into the B16-F1 tumor. Also the B16-F1 tumor fluorescence intensity at the tumor site was stronger than that of dFv. This study indicates that the recombinant protein dFv-ePD1 has an intensive melanoma-binding capability and exerts potent therapeutic efficacy against melanoma. The novel format of the PD-L1-blocked agent may play an active role in antitumor immunotherapy.
Abstract
Recent studies showed that the PD-1/PD-L1 checkpoint blockade is a dramatic therapy for melanoma by enhancing antitumor immune activity. Currently, major strategies for the PD-1/PD-L1 blockade have mainly focused on the use of antibodies and compounds. Seeking an alternative approach, others employ endogenous proteins as blocking agents. The extracellular domain of PD-1 (ePD1) includes the binding site with PD-L1. Accordingly, we constructed a PD-1-based recombinantly tailored fusion protein (dFv-ePD1) that consists of bivalent variable fragments (dFv) of an MMP-2/9-targeted antibody and ePD1. The melanoma-binding intensity and antitumor activity were also investigated. We found the intense and selective binding capability of the protein dFv-ePD1 to human melanoma specimens was confirmed by a tissue microarray. In addition, dFv-ePD1 significantly suppressed the migration and invasion of mouse melanoma B16-F1 cells, and displayed cytotoxicity to cancer cells in vitro. Notably, dFv-ePD1 significantly inhibited the growth of mouse melanoma B16-F1 tumor cells in mice and in vivo fluorescence imaging showed that dFv-ePD was gradually accumulated into the B16-F1 tumor. Also the B16-F1 tumor fluorescence intensity at the tumor site was stronger than that of dFv. This study indicates that the recombinant protein dFv-ePD1 has an intensive melanoma-binding capability and exerts potent therapeutic efficacy against melanoma. The novel format of the PD-L1-blocked agent may play an active role in antitumor immunotherapy.
참고문헌 (42)
- Ostrand-Rosenberg S, "The programmed death-1 immune-suppressive pathway:barrier to antitumor immunity", J Immunol, 193, pp.3835~3841 (2014)
- Simon S, "PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?", Oncoimmunology, 7, pp.e1364828~ (2017)
- van de Ven R, "High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes", ERJ Open Res, 3, pp.1~9 (2017)
- Mittendorf EA, "PD-L1 expression in triple-negative breast cancer", Cancer Immunol Res, 2, pp.361~370 (2014)
- Brody R, "PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review", Lung Cancer, 112, pp.200~215 (2017)
- Masugi Y, "Tumour CD274(PD-L1) expression and T cells in colorectal cancer", Gut, 66, pp.1463~1473 (2017)
- Howitt BE, "Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1", PD-L1 expression, 2017, pp.6, e1277308~
- Kaunitz GJ, "Melanoma subtypes demonstrate distinct PD-L1 expression profiles", Lab Invest, 97, pp.1063~1071 (2017)
- Chemnitz JM, "SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation", J Immunol, 173, pp.945~954 (2004)
- Keir ME, "PD-1 and its ligands in tolerance and immunity", Annu Rev Immunol, 26, pp.677~704 (2008)
- Wolchok JD, "Nivolumab plus ipilimumab in advanced melanoma", N Engl J Med, 369, pp.122~133 (2013)
- Topalian SL, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", N Engl J Med, 366, pp.2443~2454 (2012)
- Cho DC, "Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC)", J Clin Oncol, 31, pp.4505~4505 (2013)
- Herbst RS, "Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients", Nature, 515, pp.563~567 (2014)
- Audrito V, "PD-L1up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p", Oncotarget, 8, pp.15894~15911 (2017)
- Obeid JM, "PD-L1, PD-L2 and PD-1 expression in metastatic melanoma:Correlation with tumor-infiltrating immune cells and clinical outcome", Oncoimmunology, 5, pp.e1235107~ (2016)
- Ribas A, "The future of cancer therapy: selecting patients likely to respond to PD1", L1blockade, 2014, pp.20, 4982~4984
- Ribas A, "Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial", Lancet Oncol, 16, pp.908~918 (2015)
- Weber JS, "Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial", Lancet Oncol, 16, pp.375~384 (2015)
- Postow MA, "Nivolumab and ipilimumab versus ipilimumab in untreated melanoma", N Engl J Med, 372, pp.2006~2017 (2015)
- Kessenbrock K, "Matrix metalloproteinases: regulators of the tumor microenvironment", Cell, 141, pp.52~67 (2010)
- Egeblad M, "New functions for the matrix metalloproteinases in cancer progression", Nat Rev Cancer, 2, pp.161~174 (2002)
- John A, "The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis", Pathol Oncol Res, 7, pp.14~23 (2001)
- Pellikainen JM, "Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis", Clin Cancer Res, 10, pp.7621~7628 (2004)
- Liu Z, "Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma", BMC Cancer, 10, pp.270~ (2010)
- Karam A, "MMPs in ovarian cancer as therapeutic targets", Anticancer Agents Med Chem, 12, pp.764~772 (2012)
- Roy R, "Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer", J Clin Oncol, 27, pp.5287~5297 (2009)
- Beckman RA, "Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors", Cancer, 109, pp.170~179 (2007)
- Li L, "Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma", World J Gastroenterol, 11, pp.4478~4483 (2005)
- Wang FQ, "Antitumor effects of the immunoconjugate composed of lidamycin and monoclonal antibody 3G11", Yao Xue Xue Bao, 38, pp.515~519 (2003)
- Qin Y, "MMP-2", 9-oriented combinations enhance antitumor efficacy of EGFR, Oncol Rep, pp.2014, 32[DOI]
- Holliger P, "Engineered antibody fragments and the rise of single domains", Nat Biotechnol, 23, pp.1126~1136 (2005)
- Zhong G, "A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice", Cancer Lett, 295, pp.124~133 (2010)
- Hidalgo M, "Development of matrix metalloproteinase inhibitors in cancer therapy", J Natl Cancer Inst, 93, pp.178~193 (2001)
- Zucker S, "Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment", Oncogene, 19, pp.6642~6650 (2000)
- Liu XJ, "Mithramycin-loaded mPEG-PLGA nanoparticles exert potent antitumor efficacy against pancreatic carcinoma", Int J Nanomedicine, 12, pp.5255~5269 (2017)
- Vanella V, "PD-L1 inhibitors in the pipeline:Promise and progress", Oncoimmunology, 7, pp.e1365209~ (2017)
- Kleffel S, "Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth", Cell, 162, pp.1242~1256 (2015)
- Clark CA, "Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma", Cancer Res, 76, pp.6964~6974 (2016)
- Almozyan S, "PD-L1promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K", AKT pathway activation, 2017, pp.141, 1402~1412
- Godefroy E, "Matrix metalloproteinase-2 conditions human dendritic cells to prime inflammatory T(H)2 cells via an IL-12- and OX40L-dependent pathway", Cancer Cell, 19, pp.333~346 (2011)
- Zhou J, "The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma in vitro and in vivo", Theranostics, 7, pp.1447~1462 (2017)